Bleeding‐related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network
- 6 April 2018
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 24 (4), 628-633
- https://doi.org/10.1111/hae.13473
Abstract
Introduction Patients suffering from von Willebrand disease (VWD) have a variety of bleeding symptoms and require both outpatient care for treatment and, in more severe cases, hospitalization. Aim To investigate the impact of having VWD on frequency of hospitalization compared to a control group and to evaluate whether regular replacement therapy (prophylaxis) is associated with reduction in the number of hospitalizations. Methods Linkage of national population‐based registries was used in the Congenital Bleeding Disorders study in Sweden (CBDS). Data were from the von Willebrand Disease Prophylaxis Network (VWD PN). Results The national registries contained 2790 subjects with a diagnosis of VWD between 1987 and 2009. A total of 13 920 age‐ and gender‐matched controls were identified. There were 2.0 times (range 1.5‐2.5) as many inpatient hospitalizations among subjects with VWD compared to controls. The most common causes of hospitalization were gastrointestinal (GI) bleeding (n = 232 as primary diagnosis), menorrhagia (n = 198) and epistaxis (n = 192). Outpatient visits per year were also twice as common among those with VWD. From the VWD PN, 105 subjects were included (VWD type 3, 52.4%; type2A, 22.9%; type 1, 12.4% and other types, 3.9%). A total of 122 hospitalizations due to bleeding episodes, dominated by GI bleeds, were analysed. Significantly fewer hospitalizations occurred after initiation of prophylaxis (75 prior to and 45 after, P = .006). Conclusion Our study indicates that subjects with VWD have a considerably higher consumption of healthcare resources compared to controls and that initiation of prophylaxis may reduce the number of hospitalizations due to bleeding.Keywords
Funding Information
- Bayer HealthCare
- Lund University Medical Faculty Foundation
- CSL Behring
This publication has 9 references indexed in Scilit:
- Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis NetworkJournal of Thrombosis and Haemostasis, 2015
- Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapyBlood Coagulation & Fibrinolysis, 2015
- Principles of care for the diagnosis and treatment of von Willebrand diseaseHaematologica, 2013
- Incidence, mortality rates and causes of deaths in haemophilia patients in SwedenHaemophilia, 2013
- Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)Haemophilia, 2012
- Non‐thrombotic‐, non‐inhibitor‐associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand’s disease: a systematic review of prospective studiesHaemophilia, 2012
- Cost and outcome: Comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitorThrombosis and Haemostasis, 2008
- The von Willebrand disease prophylaxis network: exploring a treatment conceptJournal of Thrombosis and Haemostasis, 2006
- On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcomeHaemophilia, 2003